EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Decoding fatal toxic effects in checkpoint inhibitor therapy using real‐world pharmacovigilance data and machine learning

Dongxue Yan, Beibei Lyu, Jie Yu, Siqi Bao, Zicheng Zhang, Meng Zhou, Jie Sun

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.70195 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Dongxue Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Immune Checkpoint Inhibitors, Machine Learning, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Immune checkpoint inhibitors (ICIs) improve cancer outcomes but are also associated with immune‐related adverse events (irAEs), which pose significant challenges for clinical management. Experimental Approach An observational pharmacovigilance analysis on FDA Adverse Event Reporting System was performed to identify ICI‐related adverse event (AE) signals. Fatality kinetics simulation and multivariate logistic regression were used to investigate patterns of fatal AEs and multisignal involvement. A machine learning framework, SAFE‐ICI, was developed to predict short‐term risk and outcomes of fatal irAEs occurring within the first 90 days of ICI therapy. Key Results The analysis identified 358 significant AE signals associated with ICI therapies across 18 organ systems. PD‐1/PD‐L1 therapies were associated with 54 fatal irAEs, including 23 in non‐small cell lung cancer (NSCLC), 5 in melanoma, 6 in renal cell carcinoma (RCC) and 20 in other cancers. Combination therapies were associated with 20 fatal irAEs, including 3 in NSCLC, 6 in melanoma, 7 in RCC and 4 in other cancers, with stable involvement of multiple AE signals. The SAFE‐ICI model demonstrated robust performance in predicting fatal irAE risk, successfully stratifying patients into low‐ and high‐risk phenotypes with significantly different survival benefits, in both the discovery and holdout validation cohorts. Conclusion and Implications Our findings highlight the potential of machine learning to improve pharmacovigilance systems and aid clinicians in enhancing patient outcomes during ICI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceImmune Checkpoint InhibitorsMachine LearningNeoplasmsDrug-Related Side Effects and Adverse ReactionsHumansAdverse Drug Reaction Reporting SystemsMaleFemaleMiddle Aged

Stichwörter der Autor:innen

FAERSdisproportionality analysisimmune checkpoint inhibitorimmune‐related adverse eventsmachine learning

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • School of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenzhou, China.

Zitieren

APA

Yan, D., Lyu, B., Yu, J., Bao, S., Zhang, Z., Zhou, M., & Sun, J. (2026). Decoding fatal toxic effects in checkpoint inhibitor therapy using real‐world pharmacovigilance data and machine learning. British Journal of Pharmacology. https://doi.org/10.1111/bph.70195

Vancouver

Yan D, Lyu B, Yu J, Bao S, Zhang Z, Zhou M, et al. Decoding fatal toxic effects in checkpoint inhibitor therapy using real‐world pharmacovigilance data and machine learning. British Journal of Pharmacology. 2026. doi:10.1111/bph.70195

BibTeX
@article{Yan2026,
  author = {Yan, Dongxue and Lyu, Beibei and Yu, Jie and Bao, Siqi and Zhang, Zicheng and Zhou, Meng and Sun, Jie},
  title = {Decoding fatal toxic effects in checkpoint inhibitor therapy using real‐world pharmacovigilance data and machine learning},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70195}
}
Kostenlos starten →